• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

玻璃体内注射抗血管内皮生长因子对印度人群角膜内皮细胞计数和中央角膜厚度的影响。

Effect of intravitreal anti-vascular endothelial growth factor on corneal endothelial cell count and central corneal thickness in Indian population.

作者信息

Joshi Mukesh, Naik Mayuresh P, Sarkar L

机构信息

Department of Ophthalmology, V.M.M.C and Safdarjung Hospital, Ring Road, Ansari Nagar, New Delhi, India.

Department of Ophthalmology, H.I.M.S.R and H.A.H. Centenary Hopsital, Nears GK-2, Alaknanda, New Delhi, India.

出版信息

J Family Med Prim Care. 2019 Jul;8(7):2429-2432. doi: 10.4103/jfmpc.jfmpc_314_19.

DOI:10.4103/jfmpc.jfmpc_314_19
PMID:31463271
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6691428/
Abstract

PURPOSE

To evaluate the effect of intravitreal anti-VEGF on corneal endothelial cell count and central corneal thickness as well as to compare these in phakic and pseudophakic eyes.

MATERIAL AND METHODS

The study was conducted in 102 eyes selected, as per selection criteria, over a time period of 18 months. At first patient visit, examination included: 1. Fundus examination. 2. Specular microscopy was done to look for endothelial cell count and Central corneal thickness. At second visit, Injection 0.5 mg/0.05 ml of ranibizumab was administered. Visits at day 1, day 7 and 1 month were done for Endothelial cell density and central corneal thickness was measured by specular microscope.

RESULTS

The mean CCT value in pseudophakic group was 502.08 ± 19.91, 501.9 ± 20.31, and 501.72 ± 21.55 on day 1, 7 and 30, respectively. The mean CCT value in phakic group was 506.53 ± 22.61, 505.96 ± 20.12, 505.92 ± 20.3 and 505.69 ± 21.47. The mean value of ECD in pseudophakic eyes on day 1, 7, and 30 were 2284.24 ± 299.86, 2281.39 ± 289.46 and 2284.06 ± 312.65 cells/mm, respectively. The mean value of ECD in phakic eyes on day 1, 7, and 30 were 2314.51 ± 212.08, 2313.92 ± 212.7 and 2313.63 ± 216.86 cells/mm, respectively.

CONCLUSION

There is no significant change in endothelial cell density, central corneal thickness, coefficient of variation and intraocular pressure before and after intravitreal injection over one month of follow-up. The results are similar between phakic and pseudophakic eyes.

摘要

目的

评估玻璃体内注射抗血管内皮生长因子(VEGF)对角膜内皮细胞计数和中央角膜厚度的影响,并比较有晶状体眼和人工晶状体眼的这些指标。

材料与方法

按照入选标准,在18个月的时间段内选取102只眼进行研究。患者首次就诊时,检查包括:1. 眼底检查。2. 进行镜面显微镜检查以检测内皮细胞计数和中央角膜厚度。第二次就诊时,注射0.5毫克/0.05毫升雷珠单抗。在第1天、第7天和第1个月进行随访,通过镜面显微镜测量内皮细胞密度和中央角膜厚度。

结果

人工晶状体眼组在第1天、第7天和第30天的平均中央角膜厚度(CCT)值分别为502.08±19.91、501.9±20.31和501.72±21.55。有晶状体眼组的平均CCT值分别为506.53±22.61、505.96±20.12、505.92±20.3和505.69±21.47。人工晶状体眼在第1天、第7天和第30天的内皮细胞密度(ECD)平均值分别为2284.24±299.86、2281.39±289.46和2284.06±312.65个细胞/平方毫米。有晶状体眼在第1天、第7天和第30天的ECD平均值分别为2314.51±212.08、2313.92±212.7和2313.63±216.86个细胞/平方毫米。

结论

在随访的一个月内,玻璃体内注射前后内皮细胞密度、中央角膜厚度、变异系数和眼压均无显著变化。有晶状体眼和人工晶状体眼的结果相似。

相似文献

1
Effect of intravitreal anti-vascular endothelial growth factor on corneal endothelial cell count and central corneal thickness in Indian population.玻璃体内注射抗血管内皮生长因子对印度人群角膜内皮细胞计数和中央角膜厚度的影响。
J Family Med Prim Care. 2019 Jul;8(7):2429-2432. doi: 10.4103/jfmpc.jfmpc_314_19.
2
Short term effects of intravitreal anti-vascular endothelial growth factor agents on cornea, anterior chamber, and intraocular pressure.玻璃体内抗血管内皮生长因子药物对角膜、前房和眼压的短期影响。
Cutan Ocul Toxicol. 2019 Dec;38(4):344-348. doi: 10.1080/15569527.2019.1616749. Epub 2019 May 30.
3
Corneal thickness and endothelial cell density measured by non-contact specular microscopy and pachymetry in Rhesus macaques (Macaca mulatta) with laser-induced ocular hypertension.通过非接触式镜面显微镜和测厚仪测量激光诱导性高眼压的恒河猴(猕猴)的角膜厚度和内皮细胞密度。
Exp Eye Res. 2003 Jun;76(6):671-7. doi: 10.1016/s0014-4835(03)00055-1.
4
Pars plana vitrectomy and silicone oil injection in phakic and pseudophakic eyes; corneal endothelial changes.有晶状体眼和人工晶状体眼的玻璃体切除术及硅油注入术;角膜内皮变化
J Ophthalmic Vis Res. 2014 Jul-Sep;9(3):310-3. doi: 10.4103/2008-322X.143361.
5
Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.玻璃体内雷珠单抗注射治疗有晶状体眼与无晶状体眼的新生血管性年龄相关性黄斑变性。
Retina. 2013 Mar;33(3):467-73. doi: 10.1097/IAE.0b013e3182753b2a.
6
The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness.玻璃体内抗血管内皮生长因子药物对眼压和中央角膜厚度的早期影响。
Int Ophthalmol. 2016 Oct;36(5):665-70. doi: 10.1007/s10792-016-0171-1. Epub 2016 Jan 16.
7
Evaluation of intracameral injection of ranibizumab and bevacizumab on the corneal endothelium by scanning electron microscopy.通过扫描电子显微镜评估前房内注射雷珠单抗和贝伐单抗对角膜内皮的影响。
J Ocul Pharmacol Ther. 2015 Mar;31(2):100-5. doi: 10.1089/jop.2014.0005. Epub 2015 Jan 9.
8
Effect of Repeated Intravitreal Ranibizumab and Aflibercept Injections on the Cornea in Patients with Age-Related Macular Degeneration.雷珠单抗和阿柏西普反复玻璃体内注射对年龄相关性黄斑变性患者角膜的影响
J Ophthalmol. 2020 Jun 9;2020:4928905. doi: 10.1155/2020/4928905. eCollection 2020.
9
Comparison of Anatomical and Functional Outcomes of Intravitreal Dexamethasone Implant between Phakic and Pseudophakic Eyes with Diabetic Macular Edema.比较有晶状体眼和无晶状体眼糖尿病黄斑水肿患者玻璃体内植入地塞米松植入物的解剖和功能结果。
Korean J Ophthalmol. 2020 Oct;34(5):383-391. doi: 10.3341/kjo.2019.0142. Epub 2020 Oct 5.
10
Effect of bevacizumab on human corneal endothelial cells: a six-month follow-up study.贝伐单抗对人角膜内皮细胞的影响:一项为期六个月的随访研究。
Am J Ophthalmol. 2008 Nov;146(5):688-91. doi: 10.1016/j.ajo.2008.06.002. Epub 2008 Aug 8.

引用本文的文献

1
Evaluating short-term corneal endothelial alterations post-intravitreal Anti-VEGF injections in treatment naïve eyes.评估初治眼玻璃体内注射抗血管内皮生长因子(Anti-VEGF)后短期角膜内皮的改变。
Rom J Ophthalmol. 2025 Apr-Jun;69(2):212-218. doi: 10.22336/rjo.2025.34.
2
Effect of Repeated Intravitreal Ranibizumab and Aflibercept Injections on the Cornea in Patients with Age-Related Macular Degeneration.雷珠单抗和阿柏西普反复玻璃体内注射对年龄相关性黄斑变性患者角膜的影响
J Ophthalmol. 2020 Jun 9;2020:4928905. doi: 10.1155/2020/4928905. eCollection 2020.

本文引用的文献

1
Corneal neovascularization: an anti-VEGF therapy review.角膜新生血管:抗血管内皮生长因子治疗综述。
Surv Ophthalmol. 2012 Sep;57(5):415-29. doi: 10.1016/j.survophthal.2012.01.007.
2
Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.与新生血管性年龄相关性黄斑变性的玻璃体内抗血管内皮生长因子治疗相关的持续性眼压升高。
J Glaucoma. 2012 Apr-May;21(4):241-7. doi: 10.1097/IJG.0b013e31820d7d19.
3
[Morphometric analysis of corneal endothelium after intravitreal ranibizumab (Lucentis) in age-related macular degeneration treatment].[玻璃体内注射雷珠单抗(Lucentis)治疗年龄相关性黄斑变性后角膜内皮的形态计量学分析]
Arch Soc Esp Oftalmol. 2010 Oct;85(10):329-32. doi: 10.1016/j.oftal.2010.09.011. Epub 2010 Nov 3.
4
Endothelial cells analysis after intravitreal ranibizumab (Lucentis) in age-related macular degeneration treatment: a pilot study.玻璃体内注射雷珠单抗(Lucentis)治疗年龄相关性黄斑变性后的内皮细胞分析:一项试点研究。
Br J Ophthalmol. 2010 Feb;94(2):267-8. doi: 10.1136/bjo.2008.153353.
5
Effect of bevacizumab on human corneal endothelial cells: a six-month follow-up study.贝伐单抗对人角膜内皮细胞的影响:一项为期六个月的随访研究。
Am J Ophthalmol. 2008 Nov;146(5):688-91. doi: 10.1016/j.ajo.2008.06.002. Epub 2008 Aug 8.
6
Pharmacokinetics of intravitreal ranibizumab (Lucentis).玻璃体内注射雷珠单抗(Lucentis)的药代动力学。
Ophthalmology. 2007 Dec;114(12):2179-82. doi: 10.1016/j.ophtha.2007.09.012.
7
Safety profile of bevacizumab on cultured human corneal cells.贝伐单抗对培养的人角膜细胞的安全性概况。
Cornea. 2007 Sep;26(8):977-82. doi: 10.1097/ICO.0b013e3180de1d0a.
8
Corneal avascularity is due to soluble VEGF receptor-1.角膜无血管状态归因于可溶性血管内皮生长因子受体-1。
Nature. 2006 Oct 26;443(7114):993-7. doi: 10.1038/nature05249. Epub 2006 Oct 18.
9
Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.单次玻璃体内注射后雷珠单抗(rhuFabV2)的临床前药代动力学。
Invest Ophthalmol Vis Sci. 2005 Feb;46(2):726-33. doi: 10.1167/iovs.04-0601.
10
Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing.血管内皮生长因子(VEGF)及其受体VEGFR - 2在角膜新生血管形成和伤口愈合调控中的作用
Acta Ophthalmol Scand. 2004 Oct;82(5):557-63. doi: 10.1111/j.1600-0420.2004.00312.x.